α-FMH

Synonyms: α-Fluoromethylhistidine
α-FMH (α-Fluoromethylhistidine) 是一种口服有效的组氨酸脱羧酶 (histidine decarboxylase) 抑制剂,可清除肠嗜铬样 (ECL) 细胞中的组胺,减少 ECL 细胞中分泌囊泡的数量和体积密度,但不影响肥大细胞的组胺储存,可消除 Omeprazole (MS-S71685) 诱导的 ECL 细胞空泡形成,并减少胃泌素 (gastrin) 诱发的 ECL 细胞组胺外流,同时不会改变 ECL 细胞的颗粒特性、Omeprazole 诱导的 ECL 细胞肥大、胃泌素诱发的胰抑素样免疫反应性外流,也不会影响组胺或迷走神经刺激引起的胃酸分泌,此外还能抑制基础和胃泌素刺激的胃酸分泌,降低胃泌素+IBMX (MS-X84938) 诱导的酸输出量,但不会直接影响分离壁细胞的酸生成。
产品编号: MS-X40672 CAS No.: 73804-75-8 分子式: C7H10FN3O2 分子量: 187.17
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

α-FMH (α-Fluoromethylhistidine) 是一种口服有效的组氨酸脱羧酶 (histidine decarboxylase) 抑制剂,可清除肠嗜铬样 (ECL) 细胞中的组胺,减少 ECL 细胞中分泌囊泡的数量和体积密度,但不影响肥大细胞的组胺储存,可消除 Omeprazole (MS-S71685) 诱导的 ECL 细胞空泡形成,并减少胃泌素 (gastrin) 诱发的 ECL 细胞组胺外流,同时不会改变 ECL 细胞的颗粒特性、Omeprazole 诱导的 ECL 细胞肥大、胃泌素诱发的胰抑素样免疫反应性外流,也不会影响组胺或迷走神经刺激引起的胃酸分泌,此外还能抑制基础和胃泌素刺激的胃酸分泌,降低胃泌素+IBMX (MS-X84938) 诱导的酸输出量,但不会直接影响分离壁细胞的酸生成。

生物实验数据

生物活性 α-FMH (α-Fluoromethylhistidine) is an orally effective histidine decarboxylase inhibitor that depletes histamine in enterochromaffin-like (ECL) cells, reduces the number and volume density of secretory vesicles in ECL cells without affecting histamine storage in mast cells, abolishes Omeprazole (MS-S71685)-induced ECL cell vacuolation, and reduces gastrin-evoked histamine efflux from ECL cells, while not altering ECL cell granule characteristics, Omeprazole-induced ECL cell hypertrophy, gastrin-evoked pancreastatin-like immunoreactivity efflux, or histamine- or vagal stimulation-induced gastric acid secretion, and additionally inhibits basal and gastrin-stimulated gastric acid secretion and reduces gastrin+IBMX (MS-X84938)-induced acid output, but does not directly affect acid production in isolated parietal cells.
体内研究
(In Vivo)

α-FMH (3 mg/kg/h;皮下持续输注,6 周) 可耗竭雌性 Sprague-Dawley 大鼠的 ECL 细胞组胺,减少 ECL 细胞分泌囊泡和微囊泡的数量,并改变分泌囊泡的大小,但不影响 ECL 细胞的肥大或颗粒超微结构。
α-FMH (3 mg/kg/h;皮下持续输注,6 周) 可耗竭 ECL 细胞组胺,消除奥美拉唑诱导的 ECL 细胞空泡形成,降低 ECL 细胞分泌囊泡和微囊泡的数量及体积密度,但对奥美拉唑诱导高胃泌素血症的雌性 Sprague-Dawley 大鼠中奥美拉唑引起的 ECL 细胞肥大或颗粒超微结构无影响。
α-FMH (3 mg/kg/h;皮下注射;24 h) 可使小鼠泌酸黏膜组胺水平降低约 65%,使 ECL 细胞分泌小泡消耗约 84%,并使血浆胃泌素水平升高 130%。
α-FMH (3 mg/kg/h;皮下注射;24 h) 可使大鼠泌酸黏膜组胺水平降低约 83%,使 ECL 细胞分泌小泡耗竭约 88%,使血浆胃泌素水平升高 143%,且对胃泌酸区其他内分泌细胞类型无影响。
α-FMH (3 mg/kg/h;皮下注射;24 h) 可使仓鼠泌酸黏膜组胺水平降低约 91%,使 ECL 细胞分泌小泡耗竭约 89%,并使 ECL 细胞轮廓大小减小约 33%,且对血浆胃泌素水平无影响。
α-FMH (5 mg/kg/h;s.c.;持续给药;24 小时) 通过不可逆抑制 HDC 使雄性 Sprague-Dawley 大鼠泌酸黏膜组胺耗竭 80%,但不改变其泌酸黏膜胰抑素-LI 的浓度。
α-FMH (3-5 mg/kg/h;皮下注射、口服;持续输注、单次给药;给药 2-6 天、测试前 2 小时) 可使雌性 Sprague-Dawley 大鼠的泌酸黏膜组胺水平降低 80%,抑制超过 60%的基础胃酸分泌,几乎完全消除 gastrin-17 刺激的胃酸分泌,但不会改变组胺刺激或迷走神经诱导 (胰岛素或幽门结扎) 的胃酸分泌。

Animal Model: Ross 308 (5 days old, food-deprived for 3 hours prior to injection)
Dosage: 250 nmol (alone); 250 nmol (co-injected with 10 μg oxytocin)
Administration: i.c.v.; single injection
Result: Had no significant effect on cumulative food intake compared to the control group at 30, 60, or 120 minutes post-injection.
Significantly attenuated the hypophagic effect of oxytocin at 30, 60, and 120 minutes post-injection.
Animal Model: C57BL/6 wild-type (male, 22 to 25 g weight, ischemic stroke model via 30 min middle cerebral artery occlusion followed by 24 h reperfusion, preceded by 3 h normobaric hypoxic preconditioning with 8% O2)
Dosage: 25 mg/kg
Administration: i.p.; single injection; 3 hours before hypoxic preconditioning
Result: Reversed the neuroprotective effects of hypoxic preconditioning, eliminating the reduction in infarct volume and improvement in neurologic deficit scores seen in untreated preconditioned wild-type mice.
Aggravated the reduction in peripheral cerebral blood flow during ischemia.
Prevented the hypoxia-induced increase in VEGF protein expression in the cerebral cortex.
Had no effect on infarct volume when administered alone.
Animal Model: Sprague-Dawley (female, 200-225 g at study start)
Dosage: 3 mg/kg per h
Administration: subcutaneous; continuous infusion; 6 weeks
Result: Depleted ECL-cell histamine content and exerted no effects on ECL cell profile, cytoplasm area, granule number, or volume density.
Reduced secretory vesicle number and volume density with a decreased median diameter to 165 nm, and lowered microvesicle number without altering its volume density.
Eliminated ECL cell vacuoles, reduced the secretory vesicle-to-granule ratio to 2.8, and induced large, diffuse, weakly electron-dense cores in vesicles and granules.
Animal Model: Sprague-Dawley (6 months to 1 year-old male, healthy, free of pulmonary infection)
Dosage: 0.2 mg/100 g; 0.5 mg/100 g; 1.0 mg/100 g
Administration: i.v.; single dose
Result: Determined the 50% inhibitory dose (ED50) for inhibition of mast cell histidine decarboxylation activity as 0.07 mg/100 g.
Reduced histamine formation to ~18,000 cpm (×103 cpm/105 mast cells) at 0.2 mg/100 g dose.
Reduced histamine formation to ~8,000 cpm (×103 cpm/105 mast cells) at 0.5 mg/100 g dose.
Reduced histamine formation to ~1,000 cpm (×103 cpm/105 mast cells) at 1.0 mg/100 g dose.
Animal Model: Sprague-Dawley (6 months to 1 year-old male, healthy, free of pulmonary infection)
Dosage: 0.5 mg/100 g (i.v.); 2.0 mg/100 g (s.c.)
Administration: i.v.; single dose; s.c.; single dose
Result: Caused near-complete inhibition of histidine decarboxylation at 2 hours, with recovery to ~50% of baseline activity by 6 hours and full recovery.
Caused near-complete inhibition at 2 hours, with recovery to only ~20,000 cpm (×103 cpm/105 mast cells).
Animal Model: Sprague-Dawley (6 to 7-week-old male, healthy, free of pulmonary infection)
Dosage: 1.07 mg/100 g per day
Administration: s.c.; continuous infusion; up to 6 days
Result: Reduced histamine formation to ~15,000 cpm (×103 cpm/105 mast cells) by day 1.
Reduced histamine formation to ~3,000 cpm (×103 cpm/105 mast cells) by day 2.
Maintained histamine formation at ~3,000 cpm (×103 cpm/105 mast cells) through day 6, sustaining inhibition below 10% of normal activity.
Animal Model: Sprague-Dawley (6 to 7-week-old male, healthy, free of pulmonary infection)
Dosage: 2 mg/100 g (priming); 0.9 mg/100 g per day (infusion); 2 mg/100 g (priming); 1.8 mg/100 g per day (infusion)
Administration: i.v.; single priming dose; s.c.; continuous infusion; 14 days
Result: Reduced peritoneal histamine‑forming activity in a dose‑dependent manner after 14‑day administration.
Stabilized peritoneal cell histamine content at near‑baseline levels at both doses and blocked the marked histamine elevation observed in untreated controls.
Produced body weight gains comparable to untreated controls.
Animal Model: Sprague-Dawley (6 to 7-week-old male, healthy, free of pulmonary infection, mast cell histamine depletion induced by Polymyxin B (MS-X66012))
Dosage: 2 mg/100 g (priming); 0.9 mg/100 g per day (infusion); 2 mg/100 g (priming); 1.8 mg/100 g per day (infusion)
Administration: i.v.; single priming dose; s.c.; continuous infusion; 14 days
Result: Maintained peritoneal cell histamine content at 4.6 μg at 0.9 mg/100 g per day dose after 14 days.
Maintained peritoneal cell histamine content at 2.4 μg at 1.8 mg/100 g per day dose after 14 days.
Animal Model: ddy mice (male, 8 weeks old, 22 g)
Dosage: 1 mg/kg; 5 mg/kg; 10 mg/kg; 25 mg/kg; 50 mg/kg; 100 mg/kg
Administration: i.p.; single dose
Result: Reduced brain, fundic stomach, and skin HDC activity to 10% of control at 5, 10, and 50 mg/kg within 4 h, respectively.
Dose-dependently decreased brain and stomach histamine to 40-50% of control, without affecting skin histamine.
Rapidly suppressed HDC activity in all three tissues within 1 h at 25 mg/kg.
Sustained brain HDC inhibition for 12 h (full recovery by 96 h); stomach HDC recovered by 48 h; skin HDC remained low for 48 h.
Lowered brain histamine to 50% for ≥ 48 h and stomach histamine to 40% within 8 h, while skin histamine was unchanged for 48 h.

化学信息

分子量 187.17
分子式 C7H10FN3O2
CAS No. 73804-75-8
别名 α-Fluoromethylhistidine

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础